CMS, Inc., receives FDA 510(k) clearence for Atlas-Based Autosegmentation software





CMS, Inc., an Elekta Company, and worldwide leader in radiation treatment planning and workflow management solutions, has received FDA 510(k) clearance for its new Atlas-Based Autosegmentation (ABAS) product.

CMS, Inc., an Elekta Company, and worldwide leader in radiation treatment planning and workflow management solutions, has received FDA 510(k) clearance for its new Atlas-Based Autosegmentation (ABAS) product. This clearance allows CMS to immediately begin distributing Atlas-Based Autosegmentation for clinical use in the United States.

Significantly reducing the amount of time spent creating and editing patient contours, ABAS is a software application that produces an estimate of the anatomy boundary contours needed to create a radiation treatment plan. Image segmentation, or contouring, is a time consuming component of the treatment planning process, and ABAS helps save clinicians time by providing a good starting point from which minimal editing is required.

In addition to its time-saving benefits, ABAS distinguishes itself from competing products in several ways. A stand-alone, vendor-neutral product that communicates using standard DICOM file formats for both input and output, ABAS is compatible with any radiation treatment planning system that can read standard DICOM RT structure set files.

Terry Wolf, Director of Research for CMS, an Elekta Company said, We are extremely proud and very pleased to receive clearance to distribute Atlas-Based Autosegmentation to the U.S. market.  An embodiment of our core values, ABAS is an innovative solution delivered in a vendor-neutral platform aimed at improving the quality of care.

The ABAS algorithms were developed by Dr. Xiao Han, CMS Research Scientist. Dr. Han’s work, titled, Atlas-based Auto-segmentation of Head and Neck CT Images, will be presented September 9 at the 11th Annual International Conference on Medical Image Computing and Computer Assisted Intervention in New York City.